We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
Read MoreHide Full Article
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) were down 37.2% on Friday after the company announced top-line data from two phase III studies, namely, DERBY and OAKS, which is evaluating its targeted C3 therapy, pegcetacoplan for treating adult patients with geographic atrophy (“GA”) secondary to age-related macular degeneration.
In fact, the stock has plunged 38.9% so far this year against the industry’s rise of 0.8%.
Image Source: Zacks Investment Research
Data from the OAKS study showed that monthly and every-other-month treatment with pegcetacoplan led to a significant reduction of 22% of 16%, respectively, in GA lesion growth as compared to pooled sham at 12 months – the primary endpoint.
Data from the DERBY study showed a reduction of 12% and 11%, respectively, with monthly and every-other-month treatment with pegcetacoplan, as compared to pooled sham at 12 months. The study did not meet the primary endpoint.
Pegcetacoplan was well tolerated across both studies and demonstrated a favorable safety profile. Data from the combined DERBY and OAKS studies showed that monthly and every-other-month treatment with pegcetacoplan reduced GA lesion growth by 17% and 14%, respectively.
Despite the mixed results, Apellis believes that pegcetacoplan has the potential to become the first treatment for GA, a leading cause of blindness. The company plans to submit a new drug application to the FDA for pegcetacoplan to treat GA in the first half of 2022.
Per the company, pegcetacoplan is the first investigational therapy to significantly slow the progression of GA in a phase III study.
An estimated one million people are affected by GA in the United States. Hence, if successfully developed for the given indication and upon potential approval, pegcetacoplan can become a new treatment option for such patients. Currently, there is no approved therapy for GA.
We remind investors that in May 2021, the FDA approved Empaveli (pegcetacoplan) as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”). A rare blood disorder, PNH is associated with abnormally low hemoglobin levels as the disease destroys red blood cells.
Empaveli is approved for treatment-naïve patients as well as those switching from Alexion’s [now part of AstraZeneca’s (AZN - Free Report) ] C5 inhibitor therapies for PNH, namely Soliris (eculizumab) and Ultomiris (ravulizumab).
Image: Bigstock
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) were down 37.2% on Friday after the company announced top-line data from two phase III studies, namely, DERBY and OAKS, which is evaluating its targeted C3 therapy, pegcetacoplan for treating adult patients with geographic atrophy (“GA”) secondary to age-related macular degeneration.
In fact, the stock has plunged 38.9% so far this year against the industry’s rise of 0.8%.
Image Source: Zacks Investment Research
Data from the OAKS study showed that monthly and every-other-month treatment with pegcetacoplan led to a significant reduction of 22% of 16%, respectively, in GA lesion growth as compared to pooled sham at 12 months – the primary endpoint.
Data from the DERBY study showed a reduction of 12% and 11%, respectively, with monthly and every-other-month treatment with pegcetacoplan, as compared to pooled sham at 12 months. The study did not meet the primary endpoint.
Pegcetacoplan was well tolerated across both studies and demonstrated a favorable safety profile. Data from the combined DERBY and OAKS studies showed that monthly and every-other-month treatment with pegcetacoplan reduced GA lesion growth by 17% and 14%, respectively.
Despite the mixed results, Apellis believes that pegcetacoplan has the potential to become the first treatment for GA, a leading cause of blindness. The company plans to submit a new drug application to the FDA for pegcetacoplan to treat GA in the first half of 2022.
Per the company, pegcetacoplan is the first investigational therapy to significantly slow the progression of GA in a phase III study.
An estimated one million people are affected by GA in the United States. Hence, if successfully developed for the given indication and upon potential approval, pegcetacoplan can become a new treatment option for such patients. Currently, there is no approved therapy for GA.
We remind investors that in May 2021, the FDA approved Empaveli (pegcetacoplan) as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”). A rare blood disorder, PNH is associated with abnormally low hemoglobin levels as the disease destroys red blood cells.
Empaveli is approved for treatment-naïve patients as well as those switching from Alexion’s [now part of AstraZeneca’s (AZN - Free Report) ] C5 inhibitor therapies for PNH, namely Soliris (eculizumab) and Ultomiris (ravulizumab).
Zacks Rank & Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Spero Therapeutics, Inc. (SPRO - Free Report) and Corvus Pharmaceuticals, Inc. (CRVS - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022, over the past 60 days.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 24.4% for 2021 and 21.4% for 2022, over the past 60 days.